Rolf Einar Engstad

Director/Board Member at Biotec BetaGlucans AS

65 year

Health Technology

Consumer Services

Rolf Einar Engstad active positions

Companies	Position	Start	End
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Director/Board Member	-	-

Companies	Position	Start	End
ARCTICZYMES TECHNOLOGIES ASA	Chief Tech/Sci/R&D Officer	1998-12-31	-

University of Tromso

Doctorate Degree

International

Norway

Operational

Sectoral

Health Technology	3
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Private companies	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology

Private companies

Health Technology